Drug Profile
Cancer vaccine HSPPC-96 next generation
Alternative Names: Next generation Oncophage®; Next generation vitespen; Oncophage NexGen; Vitespen NexGenLatest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Antigenics
- Class Cancer vaccines
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Sep 2006 Discontinued - Preclinical for Cancer in USA (Injection)
- 17 Jun 2003 Preclinical trials in Cancer in USA (Injection)